ERBB2 and breast carcinoma: It also contributes to resistance to conventional therapies in chronic myeloid leukemia [76], acute myeloid leukemia [77], lung cancer [78,79], esophageal adenocarcinoma [80], and colon cancer [81], as well as HER2-targeted agents lapatinib and trastuzumab in breast cancer [82].